IgA and IgG2 deficiency associated with zonisamide therapy: a case report.
OBJECTIVE
To report a previously undescribed adverse effect, IgA/IgG subclass deficiency associated with zonisamide (ZNS) therapy.


METHODS
Serum IgA and IgG subclass levels were determined by the turbidimetric immunoassay and enzyme-linked immunosorbent assay, respectively, in a 2-year-old boy with postmeningitis sequelae who was treated by ZNS.


RESULTS
Four months after initiation of ZNS, combined deficiency of IgA and IgG2 was noted. After cessation of ZNS, serum IgA level was promptly increased. IgG2 level was gradually increased, but remained subnormal after 7 months.


CONCLUSIONS
This case documents, for the first time, the action of ZNS on IgG immune system as well as IgA system. If patients with ZNS therapy showed IgA deficiency and recurrent infections, it is preferable to check serum IgG subclass concentrations as well.
Maeoka
Y
Y
Division of Child Neurology, Tottori University School of Medicine, Yonago, Japan.
Hara
T
T
Dejima
S
S
Takeshita
K
K
D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D017098:IgA Deficiency / Q000139:chemically induced*; D017099:IgG Deficiency / Q000139:chemically induced*; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D000078305:Zonisamide
D000927:Anticonvulsants; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007555:Isoxazoles; D000078305:Zonisamide